For further details and a discussion of these and other risks and uncertainties, investors are cautioned to review the Cambrex 2010 Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other filings with the U.S. Securities and Exchange Commission.
About CambrexCambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. We offer Active Pharmaceutical Ingredients ("APIs"), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit www.cambrex.com. CAMBREX CORPORATIONStatements of Profit and Loss
For the Quarters Ended March 31, 2011 and 2010
(in thousands)20112010% of% ofAmountSalesAmountSalesGross Sales
56,155Commissions, Allowances and Rebates291336Net Sales61,36355,819Other(778)274Net Revenues60,58556,093Cost of Goods Sold43,13070.0%41,60074.1%Gross Profit17,45528.3%14,49325.8%Operating ExpensesSelling, General and Administrative Expenses9,08814.7%8,79615.7%Research and Development Expenses3,0605.0%1,9853.5%Total Operating Expenses12,14819.7%10,78119.2%Operating Profit5,3078.6%3,7126.6%Other Expenses/(Inco
|SOURCE Cambrex Corporation|
Copyright©2010 PR Newswire.
All rights reserved